Life after GWAS comments
Allen Roses, director of the Deane Drug Discovery Institute at Duke University, noted that GWAS has “largely disappointed its most enthusiastic proponents” because it has not been able to identify genes responsible for complex diseases. This disappointment, he said, is because “GWAS was never meant to substitute for fine genomic sequencing,” but rather to identify regions of linkage disequilibrium in the genome that warrant further study.
After the low linkage scores, the weak GWA effect sizes, we need for whole-genome sequencing before accepting my title…